Industry Supported Symposia

Coronavirus Update

In light of the global emergency of the new coronavirus, COVID-19, the Society of Gynecologic Oncology will not conduct its 2020 Annual Meeting on Women’s Cancer, March 28-31, in Toronto, Ontario, Canada. The health and safety of meeting attendees and the patients in their care is our utmost concern. In recent weeks, countries and institutions have imposed travel bans that prevent attendance by a significant number of attendees, including meeting faculty and SGO leadership, making it impossible to conduct the meeting at this time. SGO is exploring alternatives for delivering the science and education. Please watch for email notifications and updates on the and websites. We understand this decision raises several questions. We will be updating answers to your questions at MEETING UPDATE FAQS as information becomes available. Thank you for your understanding and support.

Meeting Update faqs

Industry Supported Symposia (ISS) are unique forums for presenting educational information to Annual Meeting attendees, free of charge. Symposia sessions are scheduled during breakfast and lunch times, allowing participants the opportunity for education and networking.

Saturday, March 28, 2020 (Lunch Sessions) 12:15 p.m. – 1:45 p.m.

ISS I: Ovarian Cancer Tumor Board: Leveraging Evolving Data Sets on PARP Inhibitors to Inform Treatment Decision-Making (MTCC: 701)

ISS II: Data + Perspectives: Clinical Investigators Explore the Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Patients with Gynecologic Cancers (MTCC: 718)

Sunday, March 29, 2020 (Breakfast Session) 6:30 a.m. – 7:30 a.m.

ISS III: The Evolving Treatment Landscape in Advanced Ovarian Cancer: The Integral Role of PARP Inhibitors (MTCC: 701)

Sunday, March 29, 2020 (Lunch Sessions) 12:00 p.m. – 1:30 p.m.

ISS V: Immuno-Oncology: New Standard of Care as Monotherapy and in Combination for Gynecologic Cancers (MTCC: 701)

ISS VI: BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer (MTCC: 718)

Monday, March 30, 2020 (Breakfast Session) 6:30 a.m. – 7:30 a.m.

ISS VII: The Role of Homologous Recombination Deficiency in Precision Medicine (MTCC: 701)

Monday, March 30, 2020 (Lunch Sessions) 12:45 p.m. – 2:15 p.m.

ISS IX: Ushering in a New Age of Endometrial Cancer Treatments with Immunotherapy (MTCC: 718)

ISS X: Exploring the Science of Maintenance Therapy for Advanced Ovarian Cancer: Understanding Homologous Recombination Deficiency and Novel Targeted Strategies (MTCC: 701)

SGO does not offer CE for any of the ISS. The offering of ISS does not constitute endorsement by the SGO of the information, products or services contained therein. Registration for all symposia starts 30 minutes before the scheduled times.